• Interaction Score: 0.57

    Interaction Types & Directionality:
    substrate

    Interaction Info:

    PMIDs:
    15313215


    Sources:
    DrugBank

  • Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colon cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    25870146


    Sources:
    JAX-CKB

  • Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type uterine cancer
    Response Type decreased response
    Approval Status Preclinical

    PMIDs:
    25833835


    Sources:
    JAX-CKB

  • Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy AZD8186 + Enzalutamide
    Evidence Type Actionable
    Approval Status Preclinical

    PMIDs:
    25544636


    Sources:
    JAX-CKB CIViC

  • Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell line xenograft
    Response Type sensitive

    PMIDs:
    21191045


    Sources:
    JAX-CKB

  • Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Ipatasertib + Paclitaxel
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type predicted – sensitive

  • Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type ovarian mucinous neoplasm
    Response Type decreased response
    Approval Status Preclinical

    PMIDs:
    24100628


    Sources:
    JAX-CKB

  • Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy AZD8186 + BYL719
    combination therapy AZD8186 + Enzalutamide
    combination therapy AZD8186 + BYL719 + Enzalutamide


    Sources:
    JAX-CKB OncoKB

  • Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type sensitive

    PMIDs:
    23705826


    Sources:
    JAX-CKB

  • Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BMS-754807 + Dacomitinib
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive


    Sources:
    JAX-CKB

  • Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type prostate cancer
    Response Type sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    20797855


    Sources:
    JAX-CKB

  • Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell line xenograft
    Response Type sensitive

    PMIDs:
    20371716


    Sources:
    JAX-CKB

  • Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Preclinical - Cell culture


    Sources:
    JAX-CKB CIViC

  • Interaction Score: 0.25

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    combination therapy GSK2636771 + LGX818
    Indication/Tumor Type melanoma
    Response Type no benefit

  • Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft


    Sources:
    JAX-CKB

  • Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy GDC-0941 + MS417
    Indication/Tumor Type breast cancer
    Response Type predicted – sensitive

  • Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Navitoclax + ONC201
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive

    PMIDs:
    26474387


    Sources:
    JAX-CKB

  • Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type endometrial cancer
    Response Type no benefit
    Approval Status Phase II

  • Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Everolimus;Trastuzumab;Chemotherapy
    Drug family MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy
    Alteration PTEN:.;ERBB2:amp

  • Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type follicular thyroid carcinoma
    Response Type sensitive
    Approval Status Preclinical - Cell culture

  • Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    Response Type sensitive
    Approval Status Preclinical - Cell culture

  • Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    26177599


    Sources:
    JAX-CKB

  • Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy AZD6482 + NVP-AEW541
    Indication/Tumor Type melanoma
    Response Type no benefit

    PMIDs:
    26577700


    Sources:
    JAX-CKB

  • Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Idelalisib + MK2206
    Indication/Tumor Type diffuse large B-cell lymphoma
    Response Type predicted – sensitive

    PMIDs:
    28178345


    Sources:
    JAX-CKB

  • Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    26839307


    Sources:
    JAX-CKB

  • Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    24265152


    Sources:
    JAX-CKB

  • Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    27186432


    Sources:
    JAX-CKB

  • Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy AZD6482 + Niraparib
    combination therapy AZD6482 + Talazoparib
    combination therapy AZD6482 + Olaparib


    Sources:
    JAX-CKB

  • Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type predicted – sensitive

    PMIDs:
    28178345


    Sources:
    JAX-CKB

  • Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Drug family PIK3CA inhibitor
    Alteration PTEN:.
    Indication/Tumor Type prostate cancer

  • Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type uterine corpus sarcoma
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    22781553


    Sources:
    JAX-CKB

  • Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type ocular melanoma
    Response Type predicted – sensitive
    Approval Status Phase I

    PMIDs:
    23434733


    Sources:
    JAX-CKB

  • Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy ABT-737 + BEZ235
    Evidence Type Actionable
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    27974663


    Sources:
    JAX-CKB

  • Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type decreased response
    Approval Status Preclinical - Cell line xenograft
    Evidence Type Actionable

    PMIDs:
    23039341


    Sources:
    JAX-CKB

  • Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical
    Evidence Type Actionable
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    26589432


    Sources:
    JAX-CKB CIViC

  • Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type sensitive
    Approval Status Clinical Study


    Sources:
    JAX-CKB CIViC

  • Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Gefitinib + Linsitinib
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive

    PMIDs:
    26561558


    Sources:
    JAX-CKB

  • Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BKM120 + Trastuzumab
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type predicted – sensitive

  • Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type ovarian clear cell adenocarcinoma
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

  • Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy DETD-35 + Vemurafenib
    Approval Status Preclinical - Cell line xenograft
    combination therapy SAR260301 + Vemurafenib

  • Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    27638506


    Sources:
    JAX-CKB

  • Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy GSK2636771 + LGX818
    Indication/Tumor Type melanoma
    Response Type no benefit

    PMIDs:
    26577700


    Sources:
    JAX-CKB

  • Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Abiraterone + Ipatasertib
    Indication/Tumor Type prostate cancer
    Response Type sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    21673091


    Sources:
    JAX-CKB

  • Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell line xenograft
    Response Type sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type glioblastoma multiforme
    Evidence Type Actionable
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    27439478


    Sources:
    JAX-CKB

  • Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy GDC-0941 + PLX4720
    Indication/Tumor Type melanoma
    Response Type sensitive

    PMIDs:
    24265153


    Sources:
    JAX-CKB

  • Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Drug family EGFR mAb inhibitor
    Alteration PTEN:.

  • Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    23881923


    Sources:
    JAX-CKB

  • Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type sensitive
    Approval Status Clinical Study


    Sources:
    JAX-CKB CIViC

  • Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type no benefit
    combination therapy MLN0128 + PD-0325901
    Indication/Tumor Type colorectal cancer

    PMIDs:
    26272063


    Sources:
    JAX-CKB

  • Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

  • Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy MLN0128 + PD-0325901
    Indication/Tumor Type colorectal cancer
    Response Type no benefit


    Sources:
    JAX-CKB

  • Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    Response Type sensitive
    Approval Status Preclinical

  • Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type prostate cancer
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    25700704


    Sources:
    JAX-CKB

  • Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type prostate cancer
    Response Type not applicable
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    23270925


    Sources:
    JAX-CKB

  • Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type endometrial cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    21558396


    Sources:
    JAX-CKB

  • Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type endometrial carcinoma
    Response Type sensitive
    Approval Status Phase I

  • Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Selumetinib + BEZ235
    Indication/Tumor Type endometrial cancer
    Response Type sensitive

  • Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BMS-754807 + Dacomitinib
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive

    PMIDs:
    26561558


    Sources:
    JAX-CKB

  • Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Navitoclax + ONC201
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive

    PMIDs:
    26474387


    Sources:
    JAX-CKB

  • Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

  • Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Pemetrexed + Sorafenib
    Indication/Tumor Type Advanced Solid Tumor
    Response Type predicted – sensitive

    PMIDs:
    27213589


    Sources:
    JAX-CKB

  • Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Fulvestrant + GDC-0941
    Indication/Tumor Type estrogen-receptor positive breast cancer
    Response Type sensitive

    PMIDs:
    26733612


    Sources:
    JAX-CKB

  • Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BYL719 + MEK162
    Indication/Tumor Type melanoma
    Response Type no benefit


    Sources:
    JAX-CKB

  • Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type head and neck squamous cell carcinoma
    Response Type predicted – sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    28446642


    Sources:
    JAX-CKB

  • Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BEZ235 + Venetoclax
    Indication/Tumor Type breast cancer
    Response Type no benefit

    PMIDs:
    27974663


    Sources:
    JAX-CKB

  • Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type sensitive

    PMIDs:
    25833835


    Sources:
    JAX-CKB

  • Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    24162827


    Sources:
    JAX-CKB

  • Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy AZD8186 + Vistusertib
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Selumetinib + BEZ235
    Indication/Tumor Type endometrial cancer
    Response Type sensitive


    Sources:
    JAX-CKB

  • Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy AZD6482 + Niraparib
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    24634413


    Sources:
    JAX-CKB

  • Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    Response Type sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    22693356


    Sources:
    JAX-CKB

  • Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase I
    Response Type predicted – sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Alteration PTEN:.
    Drug family EGFR mAb inhibitor

  • Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy AZD6482 + Veliparib
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Vandetanib + Temozolomide
    Indication/Tumor Type glioblastoma multiforme
    Response Type no benefit

    PMIDs:
    25910950


    Sources:
    JAX-CKB

  • Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BGJ398 + BYL719
    Indication/Tumor Type endometrial cancer
    Response Type sensitive

    PMIDs:
    28119489


    Sources:
    JAX-CKB

  • Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type endometrial cancer
    Response Type sensitive
    Approval Status Phase II

    PMIDs:
    26951309


    Sources:
    JAX-CKB

  • Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical
    Indication/Tumor Type urinary bladder cancer
    Evidence Type Actionable


    Sources:
    JAX-CKB

  • Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Gefitinib + Linsitinib
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive

  • Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy GDC-0941 + vorinostat
    Indication/Tumor Type prostate cancer
    Response Type sensitive

    PMIDs:
    9661880 22693356


    Sources:
    JAX-CKB

  • Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy AZD6482 + Rucaparib
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive

    PMIDs:
    23565244


    Sources:
    JAX-CKB

  • Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

  • Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase II
    Response Type no benefit

  • Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy KX2-391 + Oxaliplatin
    Indication/Tumor Type ovarian mucinous neoplasm
    Response Type sensitive

    PMIDs:
    24100628


    Sources:
    JAX-CKB

  • Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


  • Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical - Cell line xenograft
    Indication/Tumor Type prostate adenocarcinoma
    combination therapy XL147 + Paclitaxel

  • Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Palbociclib + GDC-0941
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type no benefit

    PMIDs:
    27020857


    Sources:
    JAX-CKB

  • Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25672916


    Sources:
    CIViC PharmGKB

  • Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy AZD6482 + Olaparib
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14557489


    Sources:
    NCI

  • Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Gemcitabine + LY2780301
    Indication/Tumor Type breast adenocarcinoma
    Response Type sensitive

    PMIDs:
    28750271


    Sources:
    JAX-CKB

  • Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Pemetrexed + Sorafenib
    Indication/Tumor Type Advanced Solid Tumor
    Response Type predicted – sensitive

    PMIDs:
    27213589


    Sources:
    JAX-CKB

  • Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Drug family MTOR inhibitor
    Alteration PTEN:del
    Alteration PTEN:.

    PMIDs:
    None found


    Sources:
    CGI

  • Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB